These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17956715)

  • 21. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.
    Navarro M; López R; Alaña M; Ocaña A; Leno R; Sánchez F; Fonseca E; Cruz JJ
    J Palliat Med; 2007 Dec; 10(6):1226-7. PubMed ID: 18095793
    [No Abstract]   [Full Text] [Related]  

  • 22. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
    Missotten G; Verheezen Y
    Bull Soc Belge Ophtalmol; 2010; (315):23-4. PubMed ID: 21110506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
    Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
    Frei M; Bornstein MM; Schaller B; Reichart PA; Weimann R; Iizuka T
    J Oral Maxillofac Surg; 2010 Apr; 68(4):863-7. PubMed ID: 20307770
    [No Abstract]   [Full Text] [Related]  

  • 26. [Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
    Lebret T; Mouysset JL; Lortholary A; Kouri CE; Bastit L; Ktiouet M; Khemaies S; Murraciole X; Guérif S
    Bull Cancer; 2013 Mar; 100(3):247-57. PubMed ID: 23518272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
    Pouessel D; Culine S
    Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronic acid in metastatic bone disease: an audit based discussion.
    Akbar RA; Gosh SK; Khalil S; ul Haq SM
    J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
    Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F; Abrahamsson PA; Miller K
    BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
    Epperla N; Pathak R
    WMJ; 2015 Aug; 114(4):163-6; quiz 167. PubMed ID: 26436186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
    Vogelgesang SA; McMillin JM
    J Urol; 1988 Nov; 140(5):1025-7. PubMed ID: 3172354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
    Jun JH
    Korean J Ophthalmol; 2017 Aug; 31(4):368-369. PubMed ID: 28682020
    [No Abstract]   [Full Text] [Related]  

  • 36. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS; McNulty RM; Kraut EH; Turowski RC
    Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long interval zoledronic acid use in bone metastases.
    Das M
    Lancet Oncol; 2017 Feb; 18(2):e72. PubMed ID: 28089632
    [No Abstract]   [Full Text] [Related]  

  • 38. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
    Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
    Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.